FCM was performed to test whether BM-MSC-exos could promote the stemness of AML cells, and the results revealed that exosome treatment increased the expression levels of CD34 (Fig. 3a) and CD123 (Fig. 3c) in leukemia cells (P < 0.05). The gene discussed is CD34; the disease is leukemia.